Huntington's Disease epidemiology report gives a thorough understanding of the Huntington's Disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Huntington's Disease Epidemiology Forecast to 2032

DelveInsight's "Huntington&rsquo;s disease - Epidemiology Forecast-2034" report delivers an in-depth understanding of the Huntington&rsquo;s disease, historical and forecasted epidemiology as well as the Huntington&rsquo;s disease trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
<h2>Geography Covered</h2>
<ul>
<li>The United States</li>
<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
<li>Japan</li>
</ul>
Study Period: 2021-2034
<h2>Huntington&rsquo;s disease (HD) Understanding</h2>
The DelveInsight&rsquo;s Huntington&rsquo;s disease market report gives a thorough understanding of Huntington&rsquo;s disease. Huntington&rsquo;s disease (HD) is a rare, incurable, genetic, progressive neurodegenerative disorder that causes brain cells, termed as neurons, to die in several areas of the brain, together with those that help control voluntary (intentional) movement. It is passed on (inherited) from a person&rsquo;s parents and known to get worse over time, disturbing the patient&rsquo;s physical movements, emotions, and cognitive abilities. Huntington&rsquo;s disease is named after George Huntington, the physician who described it as hereditary chorea in 1872.
&nbsp;
Huntington&rsquo;s disease is caused by an error in the DNA commands that build our bodies and keep them running. DNA is made up of thousands of genes, and people with Huntington&rsquo;s disease have a small fault in one gene, chromosome 4 &ndash; one of the 23 human chromosomes that carry a person&rsquo;s entire genetic code. This defect is &ldquo;dominant,&rdquo; meaning that any person who inherits it from a parent with Huntington&rsquo;s will develop the disease in the long run. The faulty gene codes the blueprint for a protein called huntingtin. This protein&rsquo;s normal function is not yet known; however, it is called &ldquo;huntingtin&rdquo; because scientists acknowledged its defective form as the cause of Huntington&rsquo;s disease. Over time, this defective huntingtin protein leads to brain changes that cause abnormal involuntary movements, a severe decline in thinking and reasoning skills, and irritability, depression, and other mood changes. Huntington&rsquo;s disease symptoms can develop at any time, but they often first appear when people are in their 30s or 40s.
&nbsp;
The only cause behind the occurrence of Huntington&rsquo;s disease is a faulty gene that results in parts of the brain gradually becoming impaired over time. It is inherited as an autosomal dominant trait.
&nbsp;
A person is generally only at risk of developing it if one of the parents has or had it. In dominant disorders, a single copy of the disease gene (received from either the mother or father) will be expressed &ldquo;dominating&rdquo; the other normal gene and resulting in the appearance of the disease. Both men and women can get it since the risk of transmitting the disorder from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.
&nbsp;
The progression of Huntington&rsquo;s disease can be described in five stages/phases. For diagnosis specialized x-ray studies such as computerized tomography (CT) scanning, magnetic resonance imaging (MRI), or electroencephalography (EEG) may help confirm the diagnosis of Huntington&rsquo;s disease. During CT scanning, a computer and x-rays are used to create a file showing cross-sectional images of the brain.
<h2>Huntington&rsquo;s disease (HD) Epidemiology</h2>
The epidemiology section provides insights about the historical and current Huntington&rsquo;s disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
&nbsp;
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted Huntington&rsquo;s disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2021 to 2034.
&nbsp;
In the year 2021, the total prevalent cases of Huntington&rsquo;s disease were 80,170 in the 7MM which are expected to grow during the study period, i.e., 2021-2034.
&nbsp;
The disease epidemiology covered in the report provides historical as well as forecasted Huntington&rsquo;s disease epidemiology [segmented as Total Prevalent cases of Huntington&rsquo;s disease, Total Diagnosed Prevalent cases of Huntington&rsquo;s disease, Total Chorea associated cases of Huntington&rsquo;s disease, Total Diagnosed Prevalent cases of Huntington&rsquo;s disease by age group, Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage and Total Treated cases of Huntington&rsquo;s disease] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.
<h2>Country Wise- Huntington&rsquo;s disease Epidemiology</h2>
The epidemiology segment also provides the Huntington&rsquo;s disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
<h2>KOL- Views</h2>
To keep up with the current Huntington&rsquo;s disease patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Huntington&rsquo;s disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
<h2>Scope of the Report</h2>
<ul>
<li>The report covers the descriptive overview of Huntington&rsquo;s disease, explaining their causes, symptoms, pathophysiology, and genetic basis.</li>
<li>The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.</li>
<li>The report assesses the disease risk and burden and highlights the unmet needs of Huntington&rsquo;s disease.</li>
<li>The report helps to recognize the growth opportunities in the 7MM concerning the patient population.</li>
<li>The disease epidemiology covered in the report provides historical as well as forecasted Huntington&rsquo;s disease epidemiology[segmented as Total Prevalent cases of Huntington&rsquo;s disease, Total Diagnosed Prevalent cases of Huntington&rsquo;s disease, Total Chorea associated cases of Huntington&rsquo;s disease, Total Diagnosed Prevalent cases of Huntington&rsquo;s disease by age group, Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage and Total Treated cases of Huntington&rsquo;s disease] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.</li>
</ul>
<h2>Report Highlights</h2>
<ul>
<li>The companies and academics are working to assess challenges and seek opportunities that could influence Huntington&rsquo;s disease R&amp;D. The therapies under development are focused on novel approaches to treat/improve the disease condition.</li>
<li>A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Huntington&rsquo;s disease.</li>
<li>Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.</li>
</ul>
<h2>Huntington&rsquo;s disease (HD) Report Key Strengths</h2>
<ul>
<li>11 Years Forecast</li>
<li>7MM Coverage</li>
<li>Huntington&rsquo;s disease Epidemiology Segmentation</li>
</ul>
<h2>Key Questions</h2>
Epidemiology Insights:
<ul>
<li>What are the disease risk, burden, and regional/ethnic differences of Huntington&rsquo;s disease?</li>
<li>What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>What is the historical Huntington&rsquo;s disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>What would be the forecasted patient pool of Huntington&rsquo;s disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>Where will be the growth opportunities in the 7MM concerning the patient population about Huntington&rsquo;s disease?</li>
<li>Out of all 7MM countries, which country would have the highest incident population of Huntington&rsquo;s disease during the forecast period (2025-2034)?</li>
<li>At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?</li>
</ul>
<h2>Reasons to buy</h2>
<ul>
<li>The report will help in developing business strategies by understanding trends shaping and driving the Huntington&rsquo;s disease Disease market</li>
<li>To understand the future market competition in the Huntington&rsquo;s disease Disease market and Insightful review of the key market drivers and barriers</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for Huntington&rsquo;s disease Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan</li>
<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for the Huntington&rsquo;s disease Disease market</li>
<li>To understand the future market competition in the Huntington&rsquo;s disease Disease market</li>
</ul>

1. Key Insights
2. Report Introduction
3. Huntington&rsquo;s disease Market Overview at a Glance: By Country
3.1. Drug-class Share (%) Distribution of Huntington&rsquo;s disease in 2021
3.2. Drug-class Share (%) Distribution of Huntington&rsquo;s disease in 2034
4. Executive Summary of Huntington&rsquo;s disease
5. Key Events
5.1. Future Prospects
6. Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
7.1. Introduction
7.2. Cause and Inheritance of Huntington&rsquo;s disease
7.3. Risk Factors
7.4. Signs and Symptoms
7.4.1. Motor/Physical Symptoms
7.4.2. Cognitive Symptoms
7.4.3. Behavioral and Psychiatric Symptoms
7.4.4. Early Symptoms
7.4.5. Later symptoms
7.5. Stages of Huntington&rsquo;s disease
7.5.1. The Preclinical Stage
7.5.2. Stage I: Early Stage
7.5.3. Stage II: Early Intermediate Stage
7.5.4. Stage III: Late Intermediate Stage
7.5.5. Stage IV: Early Advanced Stage
7.5.6. Stage 5: Advanced Stage
7.6. Complications and Related Disorders
7.7. Pathophysiology
7.8. Diagnosis
7.8.1. Diagnostic imaging
7.8.2. Neurological exam and patient history.
7.8.3. Genetic Counseling and Testing
7.8.4. Symptomatic Testing
8. Current Treatment
8.1. Treatment Algorithm
8.2. Treatment Guidelines
8.2.1. The British Psychological Society: Evidence-based Guidance on Psychological Interventions: Huntington&rsquo;s disease (2021)
8.2.2. American Academy of Neurology (AAN): Pharmacologic Treatment of Chorea in Huntington&rsquo;s disease (2012)
8.2.3. Clinical recommendations to Guide Physical Therapy Practice for Huntington&rsquo;s disease (2021)
8.2.4. International Guidelines for the Treatment of Huntington&rsquo;s disease (2021)
8.2.5. International Expert-Based Consensus Guidelines for Huntington&rsquo;s disease (2018)
8.2.6. Clinical Guidelines Developed by the European Huntington&rsquo;s Disease Network (EHDN)
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Epidemiology Scenario in the 7MM
9.3.1. Total Prevalent cases of Huntington&rsquo;s disease in the 7MM
9.3.2. Total Diagnosed Prevalent cases of Huntington&rsquo;s disease in the 7MM
9.3.3. Total Chorea associated cases of Huntington&rsquo;s disease in the 7MM
9.3.4. Total Diagnosed Prevalent cases of Huntington&rsquo;s disease by age group in the 7MM
9.3.5. Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage in the 7MM
9.3.6. Total Treated cases of Huntington&rsquo;s disease in the 7MM
9.4. Epidemiology Scenario in the United States
9.4.1. Total Prevalent cases of Huntington&rsquo;s disease in the US
9.4.2. Total Diagnosed Prevalent cases of Huntington&rsquo;s disease in the US
9.4.3. Total Chorea associated cases of Huntington&rsquo;s disease in the US
9.4.4. Total Diagnosed Prevalent cases of Huntington&rsquo;s disease by age group in the US
9.4.5. Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage in the US
9.4.6. Total Treated cases of Huntington&rsquo;s disease in the US
9.5. Epidemiology Scenario in the EU5
9.5.1. Total Prevalent cases of Huntington&rsquo;s disease in the EU5
9.5.2. Total Diagnosed Prevalent cases of Huntington&rsquo;s disease in the EU5
9.5.3. Total Chorea associated cases of Huntington&rsquo;s disease in the EU5
9.5.4. Total Diagnosed Prevalent cases of Huntington&rsquo;s disease by age group in the EU5
9.5.5. Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage in the EU5
9.5.6. Total Treated cases of Huntington&rsquo;s disease in the EU5
9.6. Epidemiology Scenario in Japan
9.6.1. Total Prevalent cases of Huntington&rsquo;s disease in Japan
9.6.2. Total Diagnosed Prevalent cases of Huntington&rsquo;s disease in Japan
9.6.3. Total Chorea associated cases of Huntington&rsquo;s disease in Japan
9.6.4. Total Diagnosed Prevalent cases of Huntington&rsquo;s disease by age group in Japan
9.6.5. Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage in Japan
9.6.6. Total Treated cases of Huntington&rsquo;s disease in Japan
10. Unmet Needs
11. Appendix
11.1. Bibliography
11.2. Report Methodology
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight

DelveInsight's "Huntington's Disease - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Huntington's Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Huntington's Disease - Epidemiology Forecast - 2034

DelveInsight's Huntington's Disease Epidemiology Forecast 2034 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Huntington's Disease..